Hildegund Ertl Professor, Vaccine & Immunotherapy Center at the Wistar Institute in Philadelphia, USA
From what I’ve seen out there, they are probably the most promising platform.
Ian Jones Virology professor at Reading University, United Kingdom
There is enough general background data on recombinant adenovirus-based vaccines to assume the vaccine itself will be safe at the usual doses.
Ashwani Mahajan National co-convener of Swadeshi Jagran Manch, India
Once the efficacy issue is resolved, then the cost would be an important issue. My feeling is that on both these accounts, the Russian vaccine would pass the test.
Message has been successfully sent!
